Obesity following kidney transplantation and steroid avoidance immunosuppression

Clinical Transplantation

Volumn 22, Issue 3, 2008, Pages 354-359

  Elster, Eric A ^a,b,c,d,f   Leeser, David B ^a,c,d   Morrissette, Craig ^e   Pepek, Joseph M ^b   Quiko, Albin ^d   Hale, Douglas A ^a,c   Chamberlain, Christine ^a   Salaita, Christine ^a   Kirk, Allan D ^a,c   Mannon, Roslyn B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f NONE   (United States)

Author keywords

End stage renal disease; Immunosuppression; Kidney transplantation; Obesity; Steroid avoidance

Indexed keywords

ALEMTUZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBESITY; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; STEROID AVOIDANCE IMMUNOSUPPRESSIVE TREATMENT; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; OBESITY; RISK FACTORS; SIROLIMUS; STEROIDS; TACROLIMUS;

EID: 43749086656     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00792.x     Document Type: Article

References (17)

1. Wyatt SB, Winters KP, Dubbert PM. Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. Am J Med Sci 2006: 331: 166.
2. Agnani S,V achharajani VT, Gupta R, Atray NK, Vachharajani TJ. Does treating obesity stabilize chronic kidney disease? BMC Nephrol 2005: 6: 7.
3. Manson JE, Colditz GA, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990: 322: 882.
4. Bjorntorp P. Classification of obese patients and complications related to the distribution of surplus fat. Nutrition 1990: 6: 131.
5. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983: 67: 968.
6. Meier-Kriesche HU, Ojo AO, Port FK, Arndorfer JA, Cibrik DM, Kaplan B. Survival improvement among patients with end-stage renal disease: Trends over time for transplant recipients and wait-listed patients. J Am Soc Nephrol 2001: 12: 1293.
7. el-Agroudy AE, Wafa EW, Gheith OE, Shehab el-Dein AB, Ghoneim MA. Weight gain after renal transplantation is a risk factor for patient and graft outcome. Transplantation 2004: 77: 1381.
8. Johnson CP, Gallagher-Lepak S, Zhu YR et al. Factors influencing weight gain after renal transplantation. Transplantation 1993: 56: 822.
9. van den Ham EC, Kooman JP, Christiaans MH, Nieman FH, van Hooff JP. Weight changes after renal transplantation: A comparison between patients on 5-mg maintenance steroid therapy and those on steroid-free immunosuppressive therapy. Transpl Int 2003: 16: 300.
10. Rogers CC, Alloway RR, Buell JF et al. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. Transplantation 2005: 80: 26.
11. Kirk A. Results from a human tolerance trial using alemtuzumab (campath-1H) with deoxyspergualin (DSG). Am J Transplant 2003: 3: S310.
12. Knechtle SJ, Pirsch JD, Fechner JH Jr. et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003: 3: 722.
13. Swanson SJ, Hale DA, Mannon RB et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002: 360: 1662.
14. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or Campath. J Am Coll Surg 2005: 200: 505.
15. Rogers RA, Alloway RR, Buell JF et al. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. Transplantation 2005: 80: 26.
16. Rigatto C. Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial 2003: 16: 106.
17. Luo G, Falta EM, Elster EA. Steroid-free immunosuppression in organ transplantation. Curr Diab Rep 2005: 5: 305.